Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) is now available.
ASKA Pharmaceutical Holdings Co., Ltd. reported record-high sales in the third quarter of FY2024, driven by continued growth in its pharmaceutical and animal health businesses. Despite increased sales, operating profit remained stable year-over-year due to rising SG&A expenses linked to R&D progress, while the cost of sales ratio improved due to a favorable product mix.
More about ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceuticals and animal health products. The company is known for brand-name drugs such as RELUMINA and RIFXIMA.
YTD Price Performance: -6.29%
Average Trading Volume: 58,094
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen55.89B
See more data about 4886 stock on TipRanks’ Stock Analysis page.